SavedAdd your journal

Journals / Genel Tıp Dergisi / 2019 / Cilt: 29 - Sayı: 4

Boy kısalığı olan çocukların serum ürotensin 2 düzeylerinin igf-1 ile ilişkisi

Muhammed YAYLA
Damla ÇETİN
SEFER ÜSTEBAY
Hayrunisa BEKİS BOZKURT
Ömer ERTEKİN
Döndü Ülker ÜSTEBAY
Pages
194–200
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our study, Urotensin 2 may play a role in the pathophysiology of growth retardation and shortening in children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to evaluate the correlation between endogenous substances responsible for growth such as IGF-1 and IGFBP-3 by investigating serum levels of Urotensin 2 in children with short stature.
📊
Key Findings & Data:Material and Methods: In this study, 150 patients (short stature) and 30 healthy children were evaluated.
💡
Conclusion & Impact:Conclusion: In our study, Urotensin 2 may play a role in the pathophysiology of growth retardation and shortening in children.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to evaluate the correlation between endogenous substances responsible for growth such as IGF-1 and IGFBP-3 by investigating serum levels of Urotensin 2 in children with short stature. Material and Methods: In this study, 150 patients (short stature) and 30 healthy children were evaluated. These were divided into 5 groups, including control, family short stature, structural short stature, malnutrition and celiac disease.The IGF-1 and IGFBP-3 levels were determined as low or normal in these groups. Results: Serum Urotensin 2 levels were found to be higher in structural short stature, malnutrition and celiac disease with low IGF-1 levels and familial short stature with normal IGF-1 levels than control. According to IGFBP-3 levels, Urotensin2 levels were higher in all groups compared to control. Conclusion: In our study, Urotensin 2 may play a role in the pathophysiology of growth retardation and shortening in children.

Özet

Amaç: Çalışmamızda boy kısalığı olan çocuklardaki Ürotensin 2’nin serum düzeylerini araştırarak İGF-1 ve İGFBP-3 gibi büyümeden sorumlu olan endojen maddeler arasındaki korelasyonu değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmamızda 150 hasta ve 30 sağlıklı çocuk değerlendirmeye alındı. Bunlar kontrol, ailevi boy kısalığı, yapısal boy kısalığı, malnütrisyon ve çölyak olacak şekilde 5 gruba ayrıldı. Bunlarda kendi içinde İGF-1 ve İGFBP-3 düzeyleri düşük yada normal olacak şekilde gruplandırıldı. Bulgular: İGF-1 düzeyi normal olan ailevi boy kısalığı olan çocukların, düşük İGF-1 düzeyi olan yapısal boy kısalığı, malnütrisyonlu ve çölyak grubundaki çocukların serum Ürotensin 2 düzeyleri kontrol grubuna göre yüksek bulunmuştur. İGFBP-3 düzeylerine göre ise tüm gruplarda Ürotensin 2 düzeyi kontrole göre yüksek bulunmuştur. Sonuç: Çalışmamızda Ürotensin 2’nin çocuklarda büyüme gelişme geriliği ve boy kısalığı fizyopatolojisinderol alabileceği düşünülmektedir.

🔖

Cite This Article

YAYLA, M., ÇETİN, D., ÜSTEBAY, S., BOZKURT, H. B., ERTEKİN, Ö., ÜSTEBAY, D. Ü. (2019). Boy kısalığı olan çocukların serum ürotensin 2 düzeylerinin igf-1 ile ilişkisi. Genel Tıp Dergisi, Cilt: 29 - Sayı: 4, 194–200. https://ajindex.com/articles/158852

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018;14:285-300
  2. Wang B, Qin C, Zhang C, et al. Differential involvement of signaling pathways in the regulation of growth hormone release by somatostatin and growth hormone-releasing hormone in orange-spotted grouper (Epinephelus coioides). Mol Cell Endocrinol 2014;382:851-9
  3. Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab 2016;30:737-47
  4. Wong SC, Dobie R, Altowati MA, et al. Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. Endocr Rev 2016;37:62-110
  5. Murray PG, Clayton PE, Chernausek SD. A genetic approach to evaluation of short stature of undetermined cause. Lancet Diabetes Endocrinol 2018;6:564-74
  6. Boucher J, Softic S, El Ouaamari A, et al. Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Develop- 7. Soni H, Adebiyi A. Urotensin II-induced store-operated Ca(2+) entry contributes to glomerular mesangial cell proliferation and extracellular matrix protein production under high glucose conditions. Sci Rep 2017;7:18049
  7. Matsumoto T, Watanabe S, Kobayashi S, et al. Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. Rejuvenation Res 2017;20:134-45
  8. Cadirci E, Halici Z, Yayla M, et al. Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats. Peptides 2016;82:35-43
  9. Satiroglu O, Durakoglugil ME, Cetin M, et al. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow. Interv Med Appl Sci 2016;8:158-63
  10. Malagon MM, Molina M, Gahete MD, et al. Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. Peptides 2008;29:711-20
  11. Rivas RJ, Nishioka RS, Bern HA. In vitro effects of somatostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. Gen Comp Endocrinol 1986;63:245-51
  12. Sun C, Duan D, Li B, et al. UII and UT in grouper: cloning and effects on the transcription of hormones related to growth control. J Endocrinol 2014;220:35-48
  13. Argente J, Luis AP-J. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab 2018;32:499- 522
  14. Gönç EN,